239 related articles for article (PubMed ID: 26008940)
1. Impact of multiple sclerosis relapse: The NARCOMS participant perspective.
Nickerson M; Cofield SS; Tyry T; Salter AR; Cutter GR; Marrie RA
Mult Scler Relat Disord; 2015 May; 4(3):234-40. PubMed ID: 26008940
[TBL] [Abstract][Full Text] [Related]
2. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
[TBL] [Abstract][Full Text] [Related]
3. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
Hadjimichael O; Vollmer T; Oleen-Burkey M;
Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
[TBL] [Abstract][Full Text] [Related]
4. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.
Nickerson M; Marrie RA
BMC Neurol; 2013 Sep; 13():119. PubMed ID: 24016260
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.
Lo AC; Hadjimichael O; Vollmer TL
Mult Scler; 2005 Feb; 11(1):33-40. PubMed ID: 15732264
[TBL] [Abstract][Full Text] [Related]
7. Validation of an algorithm to detect severe MS relapses in administrative health databases.
Marriott JJ; Chen H; Fransoo R; Marrie RA
Mult Scler Relat Disord; 2018 Jan; 19():134-139. PubMed ID: 29223870
[TBL] [Abstract][Full Text] [Related]
8. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
[TBL] [Abstract][Full Text] [Related]
9. High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.
Doesburg D; Vennegoor A; Uitdehaag BMJ; van Oosten BW
Mult Scler Relat Disord; 2019 Jun; 31():32-37. PubMed ID: 30901702
[TBL] [Abstract][Full Text] [Related]
10. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: relapses and timing of remissions.
Iuliano G; Napoletano R; Esposito A
Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.
Mäurer M; Comi G; Freedman MS; Kappos L; Olsson TP; Wolinsky JS; Miller AE; Dive-Pouletty C; Bozzi S; O'Connor PW
Mult Scler Relat Disord; 2016 May; 7():33-40. PubMed ID: 27237754
[TBL] [Abstract][Full Text] [Related]
13. A randomized crossover study of bee sting therapy for multiple sclerosis.
Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
[TBL] [Abstract][Full Text] [Related]
14. The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapies.
Duddy M; Lee M; Pearson O; Nikfekr E; Chaudhuri A; Percival F; Roberts M; Whitlock C
Mult Scler Relat Disord; 2014 Jul; 3(4):450-6. PubMed ID: 25877056
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes.
Diržiuvienė B; Mickevičienė D
Mult Scler Relat Disord; 2022 Mar; 59():103558. PubMed ID: 35123292
[TBL] [Abstract][Full Text] [Related]
17. Patients' experiences of self-identification, seeking support, and anticipation of potential relapse in multiple sclerosis.
Wicks CR; Sloan R; DiMauro S; Thompson EL; Billington S; Webb M; Pepper G
Mult Scler Relat Disord; 2021 Nov; 56():103259. PubMed ID: 34628265
[TBL] [Abstract][Full Text] [Related]
18. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
19. Persistent pain and uncomfortable sensations in persons with multiple sclerosis.
Hadjimichael O; Kerns RD; Rizzo MA; Cutter G; Vollmer T
Pain; 2007 Jan; 127(1-2):35-41. PubMed ID: 16949751
[TBL] [Abstract][Full Text] [Related]
20. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.
Kobelt G; Berg J; Atherly D; Hadjimichael O
Neurology; 2006 Jun; 66(11):1696-702. PubMed ID: 16769943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
